Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.

@article{Simonson1997EfficacySA,
  title={Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.},
  author={Donald C Simonson and Ione A Kourides and Mark Feinglos and Harry Shamoon and Christine T. Fischette},
  journal={Diabetes care},
  year={1997},
  volume={20 4},
  pages={597-606}
}
OBJECTIVE To investigate the efficacy, safety, and dose-response characteristics of an extended-release preparation of glipizide using the gastrointestinal therapeutic system (GITS) on plasma glucose, glycosylated hemoglobin (HbA1c), and insulin secretion to a liquid-mixed meal in NIDDM patients. RESEARCH DESIGN AND METHODS Two prospective, randomized, double-blind, placebo-controlled, multicenter clinical trials were performed in 22 sites and 347 patients with NIDDM (aged 59 +/- 0.6 years… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

Similar Papers

Loading similar papers…